Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Othman J, Potter N, Ivey A, Jovanovic J, et al. Blood 2024;143:1931-1936.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Othman J, Potter N, Ivey A, Jovanovic J, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 2024;143:1931-1936.
PMID: 38364112